meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cabozantinib
nivolumab based treatment
nivolumab alone
versus all
vs mTOR inhibitors
vs everolimus
vs VEGF(R) inhibitor
vs cabozantinib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab plus cabozantinib
title
nivolumab alone
title
cabozantinib
title
everolimus
title
CONTACT-03, 2023 NCT04338269 metastatic/advanced RCC (mRCC) - 2nd line (L2) 263/259
CheckMate 025, 2015 NCT01668784 metastatic/advanced RCC (mRCC) - 2nd line (L2) 410/411
Pathology:
metastatic/advanced RCC (mRCC) - 2nd line (L2);
metastatic/advanced RCC (mRCC) - 2nd line (L2)
CONTACT-03, 2023
CheckMate 025, 2015
atezolizumab plus cabozantinib
1
T1
nivolumab alone
1
T1
cabozantinib
0
T0
everolimus
0
T0